JP2005528884A - Ｍｎ結合および細胞接着中和活性を有するヒト抗体 - Google Patents

Ｍｎ結合および細胞接着中和活性を有するヒト抗体 Download PDF

Info

Publication number
JP2005528884A
JP2005528884A JP2003536404A JP2003536404A JP2005528884A JP 2005528884 A JP2005528884 A JP 2005528884A JP 2003536404 A JP2003536404 A JP 2003536404A JP 2003536404 A JP2003536404 A JP 2003536404A JP 2005528884 A JP2005528884 A JP 2005528884A
Authority
JP
Japan
Prior art keywords
seq
antibody
nos
host cell
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003536404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005528884A5 (https=
Inventor
タケウチ，トシヒコ
デウボワ−ストリングフエロー，ナタリー
マーフイー，ジヨン・イー
リンケンバーガー，ジユリー
Original Assignee
バイエル・フアーマシユーチカルズ・コーポレーシヨン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイエル・フアーマシユーチカルズ・コーポレーシヨン filed Critical バイエル・フアーマシユーチカルズ・コーポレーシヨン
Publication of JP2005528884A publication Critical patent/JP2005528884A/ja
Publication of JP2005528884A5 publication Critical patent/JP2005528884A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2003536404A 2001-10-18 2002-10-18 Ｍｎ結合および細胞接着中和活性を有するヒト抗体 Pending JP2005528884A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34365701P 2001-10-18 2001-10-18
US37771602P 2002-05-02 2002-05-02
PCT/US2002/033470 WO2003033674A2 (en) 2001-10-18 2002-10-18 Human antibodies that have mn binding and cell adhesion-neutralizing activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010020670A Division JP2010260845A (ja) 2001-10-18 2010-02-01 Ｍｎ結合および細胞接着中和活性を有するヒト抗体

Publications (2)

Publication Number Publication Date
JP2005528884A true JP2005528884A (ja) 2005-09-29
JP2005528884A5 JP2005528884A5 (https=) 2006-01-05

Family

ID=26993561

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003536404A Pending JP2005528884A (ja) 2001-10-18 2002-10-18 Ｍｎ結合および細胞接着中和活性を有するヒト抗体
JP2010020670A Pending JP2010260845A (ja) 2001-10-18 2010-02-01 Ｍｎ結合および細胞接着中和活性を有するヒト抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010020670A Pending JP2010260845A (ja) 2001-10-18 2010-02-01 Ｍｎ結合および細胞接着中和活性を有するヒト抗体

Country Status (18)

Country Link
US (2) US7462696B2 (https=)
EP (1) EP1438339A4 (https=)
JP (2) JP2005528884A (https=)
KR (1) KR20050037478A (https=)
CN (1) CN1606569A (https=)
AR (1) AR036833A1 (https=)
BR (1) BR0213968A (https=)
CA (1) CA2463943A1 (https=)
CO (1) CO5370684A1 (https=)
DO (1) DOP2002000494A (https=)
HU (1) HUP0600335A2 (https=)
IL (1) IL161411A0 (https=)
MX (1) MXPA04003508A (https=)
PE (1) PE20030473A1 (https=)
PL (1) PL374304A1 (https=)
RU (1) RU2317998C2 (https=)
UY (1) UY27499A1 (https=)
WO (1) WO2003033674A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009519341A (ja) * 2005-12-12 2009-05-14 バイエル・ヘルスケア・エルエルシー 抗ｍ抗体およびそれらを使用する方法
JP2015091836A (ja) * 2008-05-30 2015-05-14 エックスバイオテク, インコーポレイテッドXbiotech, Inc. インターロイキン１α抗体及び有用な方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7504364B2 (en) 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
US7469076B2 (en) 2003-09-03 2008-12-23 Receptors Llc Sensors employing combinatorial artificial receptors
WO2004075855A2 (en) * 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
EP1613737A4 (en) 2003-03-28 2008-12-03 Receptors Llc ARTIFICIAL RECEPTORS COMPRISING REVERSIBLE IMMOBILIZED CONSTRUCTION BLOCKS AND METHODS
EP1664778A2 (en) * 2003-09-03 2006-06-07 Receptors LLC Nanodevices employing combinatorial artificial receptors
US7884052B2 (en) 2004-09-03 2011-02-08 Receptors Llc Combinatorial artificial receptors including tether building blocks on scaffolds
EP1789792A2 (en) 2004-09-11 2007-05-30 Receptors LLC Combinatorial artificial receptors including peptide building blocks
US20140273033A1 (en) * 2007-04-12 2014-09-18 Universiteit Hasselt Biomarkers for multiple sclerosis
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
CN106662578B (zh) * 2014-04-03 2021-11-12 艾勒詹尼斯有限责任公司 用于检测食物变态反应的肽、试剂和方法
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939598A (en) * 1990-01-12 1999-08-17 Abgenix, Inc. Method of making transgenic mice lacking endogenous heavy chains
WO2000024913A2 (en) * 1998-10-23 2000-05-04 Bayer Corporation Mn gene and protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6297051B1 (en) * 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
AU2861695A (en) * 1994-06-15 1996-01-05 Ciba Corning Diagnostics Corp. Mn gene and protein
US6689744B2 (en) * 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939598A (en) * 1990-01-12 1999-08-17 Abgenix, Inc. Method of making transgenic mice lacking endogenous heavy chains
WO2000024913A2 (en) * 1998-10-23 2000-05-04 Bayer Corporation Mn gene and protein

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009519341A (ja) * 2005-12-12 2009-05-14 バイエル・ヘルスケア・エルエルシー 抗ｍ抗体およびそれらを使用する方法
JP2012211153A (ja) * 2005-12-12 2012-11-01 Bayer Healthcare Llc 抗ｍ抗体およびそれらを使用する方法
JP2015091836A (ja) * 2008-05-30 2015-05-14 エックスバイオテク, インコーポレイテッドXbiotech, Inc. インターロイキン１α抗体及び有用な方法

Also Published As

Publication number Publication date
US20030077277A1 (en) 2003-04-24
HUP0600335A2 (en) 2006-08-28
PE20030473A1 (es) 2003-06-26
DOP2002000494A (es) 2004-05-31
JP2010260845A (ja) 2010-11-18
CA2463943A1 (en) 2003-04-24
PL374304A1 (en) 2005-10-03
US20100240100A1 (en) 2010-09-23
UY27499A1 (es) 2003-05-30
WO2003033674A3 (en) 2003-08-21
KR20050037478A (ko) 2005-04-22
MXPA04003508A (es) 2004-07-22
IL161411A0 (en) 2004-09-27
RU2317998C2 (ru) 2008-02-27
CN1606569A (zh) 2005-04-13
CO5370684A1 (es) 2004-02-27
EP1438339A2 (en) 2004-07-21
RU2004115112A (ru) 2005-04-27
WO2003033674A2 (en) 2003-04-24
EP1438339A4 (en) 2008-08-27
AR036833A1 (es) 2004-10-06
BR0213968A (pt) 2005-05-10
US7462696B2 (en) 2008-12-09

Similar Documents

Publication Publication Date Title
US20100240100A1 (en) Human antibodies that have mn binding and cell adhesion-neutralizing activity
CN109963591B (zh) B7h3抗体-药物偶联物及其医药用途
JP5608091B2 (ja) 抗メソセリン抗体およびその使用
ES2535813T3 (es) Anticuerpos recombinantes y fragmentos que reconocen el gangliósido N-glicolil-GM3 y su uso en el diagnóstico y tratamiento de tumores
KR102662387B1 (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
US7091323B2 (en) Human TIMP-1 antibodies
US8722587B2 (en) Single chain fragment variable antibody libraries and uses thereof
JP2021510078A (ja) Ｐｄ−ｌ１抗体、その抗原結合フラグメント、及びその製薬学的使用
JP7624478B2 (ja) 癌治療において壊死を標的とするヒト化抗核抗体
US6777540B1 (en) Humanized immunoglobulin reacting specifically with Fas ligand or active fragments thereof and region inducing apoptosis originating in Fas ligand
US7285640B2 (en) Antibody to stem cell factor
KR101501736B1 (ko) 인간 및 마우스에서 발현하는 ｌ1ｃａｍ에 특이적으로 결합하는 재조합 단일클론항체 및 그 이용
RU2534890C2 (ru) Антитела против mst1r и их применение
KR20230146521A (ko) 항체-피롤로벤조디아제핀 유도체 접합체
AU2002349969A1 (en) Human antibodies that have MN binding and cell adhesion-neutralizing activity
JP2013502428A (ja) 増殖性および病原性疾患の治療のための方法および組成物
CA2381099A1 (en) Melanoma associated antigen (hmw-maa) defined by a monoclonal antibody
CN116265489A (zh) 同时靶向人CD73及人TGFβ的双功能融合蛋白、其制备方法和用途
ZA200402837B (en) Human antibodies that have MN binding and cell adhesion-neutralizing activities

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080801

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081107

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20081107

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20090728

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090731

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20090908

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100201

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100317

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120118

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120220

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120319

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120326